Management of Type 2 Diabetes: 2021 ADA Recommendations
[Pages:86]Management of Type 2 Diabetes: 2021 ADA Recommendations
Natalie Levy, MD Associate Professor, NYU School of Medicine Director, Bellevue Primary Care Diabetes Program
2_5_21
Type 2 Diabetes: ADA management recommendations
? Blood Glucose ? Blood Pressure ? LDL ? If time allows
? Pre Diabetes ? DM Outreach in the Time of Covid
Blood Glucose
? Blood Glucose-lowering Medication Framework: ADA 2021 ? Review GLP1-RA ? Review SGLT2i ? Operationalize This ? Pop-Quiz Questions
GLP1-RA
? Glucagon-like Peptide 1 Receptor Agonist ? GLP1: Secreted by the L cells in the small intestine
? Increase Insulin ? Decrease Glucagon ? Slow gastric emptying ? Increase satiety ? Improved Blood Glucose Control
Patients
MACE Hazard ratio
Liraglutide Leader 2016
81% ASCVD
0.87 (0.78-0.97)
HHF Hazard Ratio
Macro-albuminuria Hazard Ratio
0.87 (0.73-1.05)
0.74 (0.60-0.91)
SQ Semaglutide Sustain 2016
72% ASCVD
0.74 (0.58-0.95)
Dulaglutide Rewind 2019
31% ASCVD
0.88 (0.79-0.99)
1.11 (.77-1.61)
0.54 (0.37-0.57)
0.93 (0.77-1.12)
0.77 (0.68-0.87)
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- type 2 diabetes mellitus
- type 1 vs type 2 diabetes chart
- type 2 diabetes medications list
- type 2 diabetes weekly menu
- type 2 diabetes breakfast recipes
- type 2 diabetes education pdf
- type 2 diabetes mellitus definition
- type 2 diabetes symptoms women
- management of type 2 mi
- type 2 diabetes sample menus
- type 2 diabetes with complications icd 10
- type 2 diabetes with hypertension icd 10